EDIT-301 In Vitro Gene Editing Clinical Trial
ADC评论
July 30, 2022
Recently, Editas Medicine announced data from the Phase I/II RUBY trial of EDIT-301 therapy for the treatment of sickle cell anemia (SCD), with the first
